Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022 is registered in ClinicalTrials.gov with Nurix Therapeutics, Inc. as lead sponsor.

NCT NCT05131022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05131022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
Lead sponsor
Nurix Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 13, 2022
Completion date
January 31, 2028
Enrollment
572 (estimated)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), diffuse large b cell lymphoma (dlbcl), follicular lymphoma (fl), mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), primary central nervous system lymphoma (pcnsl), secondary central nervous system lymphoma (scnsl), small lymphocytic lymphoma (sll), waldenstrom macroglobulinemia (wm)